Stewart Alan Factor

Stewart Alan Factor's AcademicInfluence.com Rankings

Stewart Alan Factor

Philosophy

#8168

World Rank

#11496

Historical Rank

Logic

#5198

World Rank

#6577

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Stewart Alan Factor's Degrees

Doctorate Medicine University of California, San Diego
PhD Neurosciences University of California, San Diego

Why Is Stewart Alan Factor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stewart Alan Factor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000) (921)
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease (2010) (702)
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database (2012) (546)
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome (2017) (520)
Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology (2006) (496)
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group (2007) (450)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. (1999) (417)
Sleep disorders and sleep effect in Parkinson's disease (1990) (366)
Psychogenic movement disorders: frequency, clinical profile, and characteristics. (1995) (301)
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 (2012) (274)
Mutations in GNAL cause primary torsion dystonia (2012) (260)
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease (2012) (258)
A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia (2000) (239)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia (1997) (231)
Cognitive performance of GBA mutation carriers with early-onset PD (2012) (225)
Occupation and risk of parkinsonism: a multicenter case-control study. (2009) (225)
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial (2015) (225)
Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease (2000) (223)
Longitudinal outcome of Parkinson’s disease patients with psychosis (2003) (219)
Ropinirole 24-hour prolonged release (2007) (218)
Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa (2012) (216)
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. (2001) (216)
Parkinson's disease: drug-induced psychiatric states. (1995) (207)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. (1999) (206)
Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee (2011) (200)
Parkinson's Disease: Diagnosis and Clinical Management (2007) (191)
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease (1997) (187)
The focal dystonias: Current views and challenges for future research (2013) (176)
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. (2014) (175)
Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (2017) (171)
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. (2010) (164)
The natural history of embouchure dystonia (2001) (159)
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease (2016) (157)
LRRK2 levels in immune cells are increased in Parkinson’s disease (2017) (154)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. (2016) (152)
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease (2007) (150)
Quality improvement in neurology: AAN Parkinson disease quality measures (2010) (149)
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk (2008) (145)
Physiology of freezing of gait (2016) (145)
Association of Parkinson disease with structural and regulatory variants in the HLA region. (2013) (142)
The emergin role of clozapine in the treatment of movement disorders (1997) (136)
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease (1993) (132)
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients (2007) (130)
Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. (2010) (125)
Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease (2006) (123)
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (121)
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. (2006) (121)
NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study (2015) (108)
The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia (2002) (104)
Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. (2014) (103)
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease (2018) (102)
Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial (2001) (101)
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease (2019) (101)
Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys (2007) (101)
Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval (2011) (100)
Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder (2013) (96)
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study (2006) (96)
The clinical spectrum of freezing of gait in atypical parkinsonism (2008) (95)
Exploring gene-environment interactions in Parkinson’s disease (2008) (94)
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis (2010) (94)
Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics (2006) (93)
Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. (1994) (93)
Randomized controlled trial of deutetrabenazine for tardive dyskinesia (2017) (92)
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
The natural history of the syndrome of primary progressive freezing gait. (2002) (91)
Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study (2015) (90)
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
Failure of recognition of drug‐induced parkinsonism in the elderly (2008) (89)
Primary progressive freezing gait: A syndrome with many causes (2006) (88)
Clozapine prevents recurrence of psychosis in Parkinson's disease (1992) (87)
A randomized, placebo-controlled trial of latrepirdine in Huntington disease. (2010) (86)
Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. (2015) (86)
Head injury, alpha‐synuclein Rep1, and Parkinson's disease (2012) (83)
Prior history of head trauma in Parkinson's disease (1991) (83)
A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2 (2010) (82)
The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease (2015) (81)
Trauma as an etiology of parkinsonism: A historical review of the concept (1988) (78)
Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens (2020) (77)
Freezing of gait: understanding the complexity of an enigmatic phenomenon. (2019) (75)
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance (2014) (74)
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. (2017) (72)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Diagnosis and treatment of dystonia. (2015) (70)
Quality improvement in neurology: Parkinson disease update quality measurement set (2016) (70)
Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region (2011) (69)
Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic (2014) (69)
Worsening of motor features of Parkinsonism with olanzapine (1999) (68)
The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. (2000) (66)
Long-Term Comparative Experience with Tolcapone and Entacapone in Advanced Parkinson's Disease (2001) (65)
Seizures in juvenile Huntington's disease: Frequency and characterization in a multicenter cohort (2012) (64)
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. (1995) (64)
Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited (2016) (62)
Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. (2010) (62)
Identification of a novel Parkinson’s disease locus via stratified genome-wide association study (2014) (61)
A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease (2008) (60)
Genetic association between α‐synuclein and idiopathic parkinson's disease (2008) (60)
Clinical comparison of tardive and idiopathic cervical dystonia (1998) (60)
Psychogenic tremors (1989) (58)
Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. (1995) (56)
Cognitive profile of LRRK2‐related Parkinson's disease (2015) (55)
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study (2019) (55)
A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. (2010) (54)
Disease‐related and genetic correlates of psychotic symptoms in Parkinson's disease (2011) (54)
A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease (2012) (54)
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy (2000) (53)
Secondary blepharospasm associated with structural lesions of the brain (2013) (52)
Freezing of gait subtypes have different cognitive correlates in Parkinson's disease. (2014) (52)
Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia (2005) (51)
Current status of symptomatic medical therapy in Parkinson’s disease (2008) (51)
Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens (2020) (50)
Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease (2000) (49)
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine (2014) (48)
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
β-Hexachlorocyclohexane levels in serum and risk of Parkinson's disease. (2011) (48)
Peptidoglycan recognition protein genes and risk of Parkinson's disease (2014) (47)
Cognitive correlates of hallucinations and delusions in Parkinson's disease (2014) (46)
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
The role of neurotransmitters in the development of Parkinson's disease‐related psychosis (2017) (45)
Identification of genetic modifiers of age-at-onset for familial Parkinson’s disease (2016) (45)
Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: A β-CIT imaging study (2010) (44)
Focal myopathy as a cause of anterocollis in Parkinsonism (2001) (44)
Daytime alertness in Parkinson's disease: Potentially dose‐dependent, divergent effects by drug class (2012) (44)
Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED] (2006) (44)
Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease (2013) (44)
Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. (1988) (43)
Emergency department presentations of patients with Parkinson's disease. (2000) (43)
Recent developments in drug-induced movement disorders: a mixed picture (2019) (43)
An open-label study of botulinum toxin A for treatment of tardive dystonia. (1997) (43)
Cervical dystonia severity scale reliability study (2001) (42)
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes (2016) (41)
Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status (2009) (40)
Hemichorea‐hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis (1989) (40)
In vivo detection of lateral–ventral tier nigral degeneration in Parkinson's disease (2017) (38)
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. (2013) (37)
Basal ganglia infarction as a possible cause of cervical dystonia (1993) (37)
Dopamine agonists (2013) (36)
Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease (2019) (36)
Adult-onset dystonia. (2011) (36)
Literature review (2004) (36)
Movement disorders emergencies Part 2: hyperkinetic disorders. (2011) (36)
Serum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expression (2006) (35)
Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease (2007) (35)
Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future (2017) (35)
Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. (2004) (35)
Excessive daytime sleepiness in cervical dystonia. (2009) (34)
Focal dystonia secondary to cerebral toxoplasmosis in a patient with acquired immune deficiency syndrome (1991) (34)
Risperidone and parkinson's disease (2002) (34)
Early combination therapy with bromocriptine and levodopa in parkinson's disease (1993) (34)
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia (2019) (33)
Sleep and impulsivity in Parkinson's disease. (2013) (33)
Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: A clinico-pathological case report (1994) (33)
Fatal Parkinsonism–hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation (2007) (33)
Possible tardive dystonia resulting from clozapine therapy (1999) (32)
Daytime REM sleep in Parkinson's disease. (2013) (31)
How long does it take to diagnose cervical dystonia? (2013) (31)
Trial of dextromethorphan/quinidine to treat levodopa‐induced dyskinesia in Parkinson's disease (2017) (30)
Cocaine and tourette's syndrome (1988) (29)
Delayed‐onset dystonia associated with corticospinal tract dysfunction (1988) (29)
Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts (2018) (29)
Vitamin E therapy in Parkinson's disease. (1990) (29)
Clinimetric testing of the comprehensive cervical dystonia rating scale (2016) (28)
The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. (2001) (28)
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications (2018) (28)
VMAT2 inhibitors for the treatment of tardive dyskinesia (2018) (28)
Diabetes mellitus among parkinsonian patients treated chronically with clozapine. (2004) (27)
A Functional Magnetic Resonance Imaging Study of Head Movements in Cervical Dystonia (2016) (27)
Temporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulation. (2015) (26)
Acute delirium after withdrawal of amantadine in Parkinson's disease (1998) (26)
Tardive dyskinesia due to aripiprazole: report of 2 cases. (2009) (26)
False‐positive SCA8 gene test in a patient with pathologically proven multiple system atrophy (2005) (25)
Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease (2017) (25)
Transient benefit of amantadine in Parkinson's disease: The facts about the myth (1999) (24)
Dystonia & tremor: A cross-sectional study of the dystonia coalition cohort. (2020) (23)
Dystonia in AIDS: Report of four cases (2003) (23)
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. (2014) (22)
Paraquat and Parkinson's disease (1987) (21)
Saccades in Progressive Supranuclear Palsy–Maladapted, Irregular, Curved, and Slow (2017) (21)
Movement disorders emergencies. Part 1: Hypokinetic disorders. (2011) (21)
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. (2006) (20)
Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson’s disease (2004) (20)
Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history (2007) (19)
Propranolol therapy for Tardive dyskinesia: A retrospective examination. (2016) (19)
Adult‐onset tics associated with peripheral injury (1997) (19)
Platelet morphology in Parkinson's disease: An electron microscopic study (1994) (19)
Movement disorders emergencies. (2015) (19)
Drug-Induced Movement Disorders (1992) (18)
Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders (2016) (18)
Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia (2002) (18)
The initial treatment of Parkinson's disease (2000) (18)
Pharmacology of atypical antipsychotics. (2002) (17)
Mosaic pattern of gliosis in the neostriatum of a north american man with craniocervical dystonia and parkinsonism (1997) (17)
Globus pallidus deep brain stimulation for adult-onset axial dystonia. (2014) (17)
Tardive Dyskinesia (2011) (15)
Imaging Parkinsonian Pathology in Substantia Nigra with MRI (2018) (15)
LRRK 2 levels in immune cells are increased in Parkinson ’ s disease (15)
Management of Tardive Syndrome: Medications and Surgical Treatments (2020) (14)
Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson’s Disease. A Perspective (2013) (14)
Parkinsonism-Hyperpyrexia Syndrome in Parkinson’s Disease (2013) (14)
Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review (2020) (14)
Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment (2012) (14)
Potential mechanisms for low uric acid in Parkinson disease (2016) (13)
Progressive supranuclear palsy. (2007) (13)
Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice (2020) (13)
Propranolol therapy for tardive dyskinesia revisited (2012) (13)
Clinical subtypes of anterocollis in parkinsonian syndromes (2012) (13)
The Current Clinical Picture Of Parkinson’S Disease (1988) (13)
A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient (2016) (12)
Multimodal assessment of nigrosomal degeneration in Parkinson's disease. (2020) (12)
'Sleep benefit' in Parkinson's disease (1998) (12)
Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease (2015) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Clinical outcomes of globus pallidus deep brain stimulation for Parkinson disease: a comparison of intraoperative MRI- and MER-guided lead placement. (2020) (12)
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease (2021) (12)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–responsive cervical dystonia (1999) (11)
An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson’s disease (2011) (11)
Early brain-stem auditory evoked responses in vertebrobasilar transient ischemic attacks. (1987) (11)
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease (2020) (11)
Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease (2018) (11)
Telemedicine in an Academic Movement Disorders Center during COVID-19 (2021) (11)
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease. (1989) (10)
A Neurodegenerative Disease Sleep Questionnaire: Principal component analysis in Parkinson's disease (2014) (10)
Ethylene glycol intoxication: a new stage in the clinical syndrome. (1987) (10)
Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease (1989) (10)
Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia (2018) (10)
A Comprehensive Approach to Care in Parkinson's Disease Adds Quality to the Current Gold Standard (2017) (10)
Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI. (2020) (10)
Chorea caused by lithium intoxication: A case report and literature review (1996) (10)
Abnormal center of mass feedback responses during balance: A potential biomarker of falls in Parkinson’s disease (2021) (10)
Lower Limb Rigidity Is Associated with Frequent Falls in Parkinson's Disease (2019) (10)
Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease (2011) (9)
Exploring human-genome gut-microbiome interaction in Parkinson’s disease (2021) (9)
Oromandibular Dystonia: A Clinical Examination of 2,020 Cases (2021) (9)
Parkinson’s disease: Initial treatment with levodopa or dopamine agonists (2001) (9)
Peripheral catecholamine output in Parkinson's disease: Effects of drug treatment (1995) (9)
Parkinson’s disease: The treatment of drug-induced hallucinations and psychosis (2001) (9)
Lurasidone‐Induced Tardive Syndrome (2019) (9)
Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. (1991) (8)
Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease (2009) (8)
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis (2021) (8)
Dystonia and Tremor (2021) (8)
Patient Acceptance and Potential Cost-Savings of Teleneurology in an Academic Outpatient Movement Disorders Practice (P1.022) (2016) (8)
Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease (2014) (8)
Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases (2005) (8)
A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodes (2020) (7)
Occupation and Risk of Parkinsonism (2016) (7)
Diagnosing functional neurological disorder: seeing the whole picture (2020) (7)
Perception of whole-body motion during balance perturbations is impaired in Parkinson’s disease and is associated with balance impairment (2019) (7)
Sleep correlates of trait executive function and memory in Parkinson's disease. (2015) (7)
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. (1989) (7)
A Metabolomic Study of Cervical Dystonia (2020) (6)
Diphasic Worsening of Freezing of Gait in Parkinson's Disease (2020) (6)
Retrospective Evaluation of Vitamin E Therapy in Parkinson's Disease (1989) (6)
Acetazolamide therapy of menstrual‐related fluctuations in parkinson's disease (1993) (6)
KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia (PL02.003) (2016) (6)
Intermittent subcutaneous apomorphine therapy in Parkinson's disease (2004) (6)
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial (2020) (6)
Quality of Life in Parkinson's Disease Patients Following Adjunctive Tolcapone Therapy: Results of an Open-Label, Multicenter, Community-Based Trial (2010) (6)
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. (2020) (6)
It's tricky: Rating alleviating maneuvers in cervical dystonia (2020) (6)
Parkinson’s disease: Motor fluctuations (1999) (6)
Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease (2021) (6)
Neuroleptic Malignant Syndrome (2008) (6)
Tibial Bone Lead, but Not Serum Polychlorinated Biphenyl, Concentrations Are Associated With Neurocognitive Deficits in Former Capacitor Workers (2013) (5)
Rapid treatment of “off” episodes (2004) (5)
Ocular Palatal Tremor Plus Dystonia: New Syndromic Association (2015) (5)
A Multi‐center Genome‐wide Association Study of Cervical Dystonia (2021) (5)
The effect of dancing on dystonia (1996) (4)
Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. (1997) (4)
Freezing of gait: A rare delayed complication of whole brain radiation. (2016) (4)
An 18F-FDG PET study of cervical muscle in parkinsonian anterocollis (2014) (4)
Reliability of the Severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) (S15.001) (2015) (4)
Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) (P2.016) (2017) (4)
Parkinson Disease from long term drug abuse: Meta-analysis of amphetamine/methamphetamine and Parkinson Disease (P6.079) (2018) (4)
Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) (S56.005) (2017) (4)
Head tremor in cervical dystonia: Quantifying severity with computer vision (2022) (4)
Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities (S56.006) (2017) (4)
Movement Disorders Emergencies Part 2 (2011) (4)
45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study (2019) (3)
Non‐motor phenotypic subgroups in adult‐onset idiopathic, isolated, focal cervical dystonia (2021) (3)
Freezing of gait that disappears: Should there be rest before rehab? (2016) (3)
Dementia in Parkinson’s Disease (2004) (3)
Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies (P2.017) (2017) (3)
Psychogenic tremors. (1989) (3)
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (2022) (3)
Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review (2022) (3)
Blockade of Cannabinoid CB 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in MPTP-Treated Rhesus Monkeys (2007) (3)
A double‐blind evaluation of ciladopa in Parkinson's disease (1987) (3)
Cerebrospinal fluid Ab42 and fractalkine are associated with Parkinson's disease with freezing of gait (2020) (3)
Internal consistency of the University of Michigan RBD Questionnaire (2014) (3)
Cervical dystonia in twins (2002) (2)
Neuromechanical Assessment of Activated vs. Resting Leg Rigidity Using the Pendulum Test Is Associated With a Fall History in People With Parkinson’s Disease (2020) (2)
Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) (S56.007) (2017) (2)
Affective Correlates of Psychosis in Parkinson's Disease (2017) (2)
Title The RAB 39 B p . G 192 R mutation causes X-linked dominant Parkinson ' s disease Permalink (2015) (2)
Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial (2022) (2)
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease (2022) (2)
The initial treatment of Parkinson's disease. (2000) (2)
A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007) (2016) (2)
Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (P4.075) (2018) (2)
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study (2022) (2)
134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies (2018) (2)
Medication-Induced Movement Disorders: VPA, lithium, amiodarone, and other non-DA (2015) (2)
Treatment of Oromandibular Dystonia (2019) (2)
The “shirt collar sign” of cervical dystonia (2017) (2)
Hold that pose: capturing cervical dystonia's head deviation severity from video (2022) (2)
Secondary Causes of Parkinsonism (2000) (2)
Initiating therapy in Parkinson's disease (2009) (2)
Faculty Opinions recommendation of Pain in Parkinson's disease: Prevalence and characteristics. (2010) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
From Null to Midline: Changes in Head Posture do Not Predictably Change Head Tremor in Cervical Dystonia (2022) (1)
Current and Emerging Treatments for Cervical Dystonia (2000) (1)
Treatment of Multiple System Atrophy (2019) (1)
46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study (2019) (1)
Letters to the editor (2000) (1)
Nonmotor Symptoms in Dystonia (2006) (1)
134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study (2020) (1)
Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) (S56.004) (2017) (1)
Advanced therapies for movement disorders in neurotherapeutics (2008) (1)
Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078) (2018) (1)
Treatment of tardive dystonia: A review (2023) (1)
Pseudonystagmus in progressive supranuclear palsy (2022) (1)
Phosphodiesterase 4 (2017) (1)
Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson’s disease (2020) (1)
The role of polymyography in the treatment of cervical dystonia: the authors reply (2016) (1)
PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and Motor Fluctuations (P1.8-017) (2019) (1)
Human-genome gut-microbiome interaction in Parkinson’s disease (2021) (1)
Clozapine (1994) (1)
James Parkinson: The Man and the Essay (2002) (1)
Current and future treatments in multiple system atrophy (2007) (1)
Comparing Quality of Parkinson Disease Care in a Comprehensive Clinic to Specialist Care (P6.372) (2016) (0)
P2.067 Resolving mode-of-inheritance and association of PRKN with PD in a comprehensive sequence and copy-number-variation (CNV) analysis of 3800 subjects (2009) (0)
Metoclopramide therapy for migraine: worth the risk? (2018) (0)
Physiological measures and anatomical correlates of subthalamic deep brain stimulation effect on gait in Parkinson's disease (2023) (0)
Faculty Opinions recommendation of Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. (2011) (0)
P2.048 Screening and selection process for deep brain stimulation: the Emory experience (2009) (0)
Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia (2018) (0)
P3.039 Polymorphisms in the transcription factor gene GATA2 and GATA-2 target region in a-synuclein (SNCA) are associated with Parkinson's disease (PD) (2009) (0)
Third Annual Huntington Disease Clinical Research Symposium (2011) (0)
Editorial: Neurotherapeutics of Movement Disorders (2013) (0)
Combination therapy for PD (1993) (0)
Delineation of the Clinical Features and Treatment Response of Oromandibular Dystonia: A Multicenter Summary of 2,057 Cases. (2020) (0)
Explorer Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson ' s disease (2017) (0)
An Explainable Spatial-Temporal Graphical Convolutional Network to Score Freezing of Gait in Parkinsonian Patients (2023) (0)
Initiating Therapy in Parkinson's Disease. Authors' reply (2009) (0)
Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease (2023) (0)
Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) (S27.004) (2014) (0)
DIAGNOSTIC CONSIDERATIONS IN EVALUATING GERIATRIC PATIENTS WITH MOVEMENT DISORDERS (2019) (0)
Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson’s Disease. A Perspective (2013) (0)
Levodopa Responsiveness Subtypes of Freezing of Gait: Results Using a Levodopa Challenge (2019) (0)
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study (2022) (0)
Clinical characteristics of oromandibular dystonia: A multicenter review of 201 caseS (2016) (0)
LRRK2 levels in immune cells are increased in Parkinson’s disease (2017) (0)
Restless Legs Symptoms and Periodic Leg Movements in Sleep Among Patients with Parkinson's Disease. (2022) (0)
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis (2021) (0)
Cramps and Spasms (2008) (0)
Reversibility of Tardive Syndromes (P04.031) (2012) (0)
151 Confirmed Safety of Deutet.rabenazine for Tardive Dyskinesia in a 3-Year Open-Label Extension Study (2020) (0)
Comprar Parkinson's Disease | Stewart A. Factor | 9781933864006 | Demos Medical Publishing (2007) (0)
139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study (2020) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
The Effects of Thalamic Deep Brain Stimulation on Gait in Essential Tremor: a Kinematic Study. (P7-11.001) (2023) (0)
Kevin Delgado Barron, MD (1929–2013) (2014) (0)
158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study (2018) (0)
Reply to: “Letter on Discussion of Gait Research” (2022) (0)
Third Annual Huntington Disease Clinical Research Symposium : Organized by the Huntington Study Group (Huntington Study Group Abstracts) (2010) (0)
A Comprehensive Approach to Parkinson’s Disease (P4.052) (2014) (0)
Head tremor after a remission of spasmodic torticollis. (1990) (0)
Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia. (2021) (0)
William J. Weiner, MD (1945–2012) (2013) (0)
Reduced norepinephrine transporter binding in Parkinson's disease with dopa responsive freezing gait (2022) (0)
Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. (2023) (0)
Treatment of Serotonin Syndrome (2019) (0)
Faculty Opinions recommendation of Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. (2011) (0)
In Memoriam: William J. Weiner, MD: June 28, 1945–December 29, 2012 (2013) (0)
Faculty Opinions recommendation of The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. (2010) (0)
Biomechanical outcomes of the pendulum test characterize individual differences in activated versus resting leg rigidity in people with Parkinson's disease (2020) (0)
P2.110 Evidence for association of high-dose levodopa therapy with intellectual and psychiatric complications of Parkinson's disease (2009) (0)
Camptocormia: a consensus for grading on a curve. (2018) (0)
Exploring human-genome gut-microbiome interaction in Parkinson’s disease (2021) (0)
Patients with Cognitive Impairment in Parkinson's Disease Benefit from Deep Brain Stimulation: A Case‐Control Study (2023) (0)
149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study (2018) (0)
Clinical Outcomes Of Deep Brain Stimulation Placement Using Intraoperative MRI for Parkinson Disease (P3.359) (2016) (0)
Appendix D: Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidenced-based review): Report of the Quality Standards Subcommitte of the American Academy of Neurology (2007) (0)
Quantitative tremor analysis of Holmes tremor: a case series (P6.066) (2018) (0)
Deep Brain Stimulation Placement Using Intraoperative MRI for Dystonia: One Year Clinical Outcomes (S30.003) (2016) (0)
Identification of a novel Parkinson’s disease locus via stratified genome-wide association study (2014) (0)
Clinical Characteristics and Natural History of Oromandibular and Lingual Dystonia (P5.399) (2016) (0)
Impact of Deep Brain Stimulation on Gait in Parkinson Disease: A Kinematic Study (2022) (0)
Treatment of Tardive Dyskinesia (2019) (0)
Driving and the Elderly (2002) (0)
An explainable spatial-temporal graphical convolutional network to score freezing of gait in parkinsonian patients (2023) (0)
Deep Brain Stimulation for Tremor in Parkinson’s Disease (2019) (0)
Phenotyping Motor-subtypes of Parkinsonism from Full-body Kinematics using Machine Learning (P6-11.007) (2023) (0)
COMBINATION THERAPY FOR PD. AUTHOR'S REPLY (1993) (0)
Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder (2013) (0)
Impact of age or time to treatment on changes in clinical outcome scores in patients treated with tPA (tissue plasminogen activator) for acute ischemic stroke: The Loyola University Medical Center (LUMC) experience (2010) (0)
Review for "Is freezing of gait correlated with postural control in patients with moderate‐to‐severe Parkinson’s disease?" (2020) (0)
Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use (2022) (0)
Medical Therapy for Fluctuations in Parkinson’s Disease (2019) (0)
Long-Term Deutetrabenazine Treatment Is Associated With Continued Improvement in Tardive Dyskinesia in the Completed 3-Year Open-Label Extension Study. (2021) (0)
Reply (2000) (0)
Letter to the editor (0)
Ropinirole as compared with levodopa in Parkinson's disease. (2000) (0)
The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease (2015) (0)
Estimating the Cumulative Risk of PD in Carriers of Parkin Mutations: The CORE-PD Study (PD4.007) (2012) (0)
Efficacy and safety of Valbenazine (NBI-98854) in subjects with tardive dyskinesia: Results of a long-term study (KINECT 3 extension) (2018) (0)
Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders (2022) (0)
Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease (2019) (0)
Letters to the editor (0)
Lower-limb rigidity is associated with frequent falls in Parkinson disease (2019) (0)
Faculty Opinions recommendation of Smoking duration, intensity, and risk of Parkinson disease. (2010) (0)
Treatment of Drenching Sweats in Parkinson’s Disease (2019) (0)
Data-Driven Discovery of Novel Motor Biomarkers for Freezing-of-Gait in Parkinsonism from Full-body Kinematics using Artificial Intelligence (P6-11.001) (2023) (0)
Editorial: Neurotherapeutics of Movement Disorders (2013) (0)
Poster 3: Frequency of Epileptic Seizures in a Population of Juvenile Huntington's Disease Patients (2010) (0)
Neurodegenerative Disease Sleep Questionnaire (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stewart Alan Factor?

Stewart Alan Factor is affiliated with the following schools:

Emory University